[1] Husain AN, Colby TV, Ordóñez NG, et al.Guidelines for pathologic diagnosis of malignant mesothelioma 2017 update of the consensus statement from the International Mesothelioma Interest Group[J]. Arch Pathol Lab Med, 2018,142:89-108. [2] Zhao J, Zuo T, Zheng R, et al. Epidemiology and trend analysis on malignant mesothelioma in China[J]. Chin J Cancer Res, 2017,29:361-368. [3] Ullah A, Waheed A, Khan J, et al. Incidence, survival analysis and future perspective of primary peritoneal mesothelioma (PPM): a population-based study from SEER database[J]. Cancers (Basel), 2022,14:942. doi: 10.3390/cancers14040942. [4] Cao S, Jin S, Cao J, et al. Advances in malignant peritoneal mesothelioma[J]. Int J Colorectal Dis, 2015,30:1-10. [5] Malgras B, Gayat E, Aoun O, et al. Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC): the RENAPE study[J]. Ann Surg Oncol, 2018,25:3271-3279. [6] Le Stang N, Bouvier V, Glehen O, et al. Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study[J]. Cancer Epidemiol, 2019,60:106-111. [7] Helm JH, Miura JT, Glenn JA, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis[J]. Ann Surg Oncol, 2015,22:1686-1693. [8] Sun L, Li C, Gao S. Diffuse malignant peritoneal mesothelioma: A review[J]. Front Surg, 2023,9:1015884. doi:10.3389/fsurg.2022.1015884. [9] Kusamura S, Kepenekian V, Villeneuve L, et al. Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up[J]. Eur J Surg Oncol, 2021,47:36-59. [10] Simon GR, Verschraegen CF, Jänne PA, et al. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase Ⅱ trial[J]. J Clin Oncol, 2008,26:3567-3572. [11] Destro A, Ceresoli GL, Falleni M, et al. EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations[J]. Lung Cancer, 2006,51:207-215. [12] Kindler HL, Karrison TG, Gandara DR, et al. Multicenter, double-blind, placebo-controlled, randomized phase Ⅱ trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma[J]. J Clin Oncol, 2012,30:2509-2515. [13] Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial[published correction appears in Lancet, 2016,387:e24. doi: 10.1016/S0140-6736(16)30084-8][J]. Lancet, 2016,387:1405-1414. [14] Raghav K, Liu S, Overman MJ, et al. Efficacy, safety, and biomarker analysis of combined PD-L1 (Atezolizu-mab) and VEGF (Bevacizumab) blockade in advanced malignant peritoneal mesothelioma[J]. Cancer Discov, 2021,11:2738-2747. |